9 Meters Biopharma (NMTR) Stock Price, News & Analysis

Company Overview

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for patients with inflammatory and autoimmune diseases. The company’s research and development efforts center on small-molecule and antibody-based programs targeting key cytokine pathways and complement components that drive tissue inflammation and immune dysregulation. By leveraging its proprietary drug discovery platform, 9 Meters Biopharma aims to advance differentiated assets through clinical proof-of-concept and into late-stage development.

The company’s lead clinical candidates include a bispecific inhibitor designed to simultaneously neutralize interleukin-6 (IL-6) and interleukin-17 (IL-17), a small-molecule antagonist of the interleukin-8 (IL-8) receptor CXCR1/2 being evaluated in chronic inflammatory lung conditions, and a complement C5 inhibitor intended for rare complement-mediated disorders. These programs reflect 9 Meters Biopharma’s strategy of addressing both common and orphan indications by modulating distinct but complementary inflammatory pathways. Preclinical and early clinical data underpin the company’s belief that dual-target approaches may offer improved efficacy or dosing convenience over existing single-target therapies.

Founded with roots in radiopharmaceutical research, 9 Meters Biopharma underwent a strategic transformation to broaden its focus into immunology. Headquartered in Boston, Massachusetts, with research collaborations in Europe and Asia, the company draws on a team of drug development veterans and scientific advisors experienced in biologics, small molecules, and translational medicine. Under the leadership of CEO Richard Nieman and a management team with deep industry expertise, 9 Meters Biopharma seeks to build a diversified pipeline of innovative treatments for patients facing significant unmet medical needs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1,375 shs
• Average Volume: 315,915 shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NMTR Stock Analysis - Frequently Asked Questions

How were 9 Meters Biopharma's earnings last quarter?

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.26.

When did 9 Meters Biopharma's stock split?

9 Meters Biopharma shares reverse split before market open on Tuesday, October 18th 2022.The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of 9 Meters Biopharma?

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 9 Meters Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NMTR
• CIK: 1551986
• Web: www.9meters.com
• Phone: (919) 275-1933
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -584.97%
• Return on Assets: -159.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.59
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,336,000
• Free Float: 13,992,000
• Market Cap: $1.04 million
• Optionable: No Data
• Beta: 1.36